성인 천식의 바이오마커와 맞춤의학
Biomarkers of adult asthma and personalized medicine
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
The concept of personalized medicine for disease diagnosis, treatment, and management, considering individual variability, including susceptibility, clinical manifestations, and drug responsiveness, is a global emerging trend in medicine, which is also inevitable. However, clinical applications of personalized medicine in the real-world practice have been limited to certain cancers so far. Furthermore, this new concept to the diagnosis and treatment of adult asthma has not been applied to clinical use. Asthma is a multifactorial and heterogeneous disease. It seems to encompass a broad spectrum of clinical manifestations with different underlying pathophysiological mechanisms. Thus, it is not easy to categorize by their clinical features alone. Endotypical categorization that considering specific pathophysiological mechanisms will be more helpful in applying the concept of personalized medicine. The success of personalized medicine depends on patient selection for precise prescription of asthma medications. In the recent years, many investigators and physicians have devoted a lot of effort to the discovery of reliable biomarkers in asthmatic patients, which will be able to actualize the personalized medicine in near future. Despite such great efforts toward investigation of good biomarkers, few things have turned out to be practical in the clinic. Easily interpretable biomarkers of asthma are necessary to assess early detection, determination of treatment, prognosis prediction, and monitoring of exacerbation. Herein, we review recent studies regarding disease classifications and biomarkers of asthma.
Abstract
The concept of personalized medicine for disease diagnosis, treatment, and management, considering individual variability, including susceptibility, clinical manifestations, and drug responsiveness, is a global emerging trend in medicine, which is also inevitable. However, clinical applications of personalized medicine in the real-world practice have been limited to certain cancers so far. Furthermore, this new concept to the diagnosis and treatment of adult asthma has not been applied to clinical use. Asthma is a multifactorial and heterogeneous disease. It seems to encompass a broad spectrum of clinical manifestations with different underlying pathophysiological mechanisms. Thus, it is not easy to categorize by their clinical features alone. Endotypical categorization that considering specific pathophysiological mechanisms will be more helpful in applying the concept of personalized medicine. The success of personalized medicine depends on patient selection for precise prescription of asthma medications. In the recent years, many investigators and physicians have devoted a lot of effort to the discovery of reliable biomarkers in asthmatic patients, which will be able to actualize the personalized medicine in near future. Despite such great efforts toward investigation of good biomarkers, few things have turned out to be practical in the clinic. Easily interpretable biomarkers of asthma are necessary to assess early detection, determination of treatment, prognosis prediction, and monitoring of exacerbation. Herein, we review recent studies regarding disease classifications and biomarkers of asthma.
참고문헌 (89)
- Lai CK, "Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC)", Thorax, 64, pp.476~483 (2009)
- 김창엽, "The Financial Burden of Asthma: A Nationwide Comprehensive Survey Conducted in the Republic of Korea", Allergy, Asthma & Immunology Research, 3(1), pp.34~38 (2011), 대한천식알레르기학회
- Anandan C, "Is the prevalence of asthma declining? Systematic review of epidemiological studies", Allergy, 65, pp.152~167 (2015)
- Moore WC, "Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program", Am J Respir Crit Care Med, 181, pp.315~323 (2010)
- Sutherland ER, "Cluster analysis of obesity and asthma phenotypes", PLoS One, 7, pp.E36631~ (2015)
- Hamburg MA, "The path to personalized medicine", N Engl J Med, 363, pp.301~304 (2010)
- Lipworth BJ, "Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis", Arch Intern Med, 159, pp.941~955 (1999)
- Wenzel S, "Severe asthma in adults", Am J Respir Crit Care Med, 172, pp.149~160 (2005)
- Busse WW, "Asthma diagnosis and treatment: filling in the information gaps", J Allergy Clin Immunol, 125, pp.740~750 (2011)
- Soukhanov AH, "Encarta world English dictionary" (1999), St Martin's Press
- Wenzel SE, "Asthma phenotypes: the evolution from clinical to molecular approaches", Nat Med, 18, pp.716~725 (2012)
- 이희원, "Clinical Characteristics of Asthma Combined with COPD Feature", Yonsei Medical Journal, 55(4), pp.980~986 (2014), 연세대학교의과대학[DOI]
- Kim TB, "Identification of asthma clusters in two independent Korean adult asthma cohorts", Eur Respir J, 41, pp.1308~1314 (2013)
- Bourdin A, "Prognostic value of cluster analysis of severe asthma phenotypes", J Allergy Clin Immunol, 134, pp.1043~1050 (2014)
- Fingleton J, "Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults", J Allergy Clin Immunol, 136, pp.601~609 (2015)
- Corren J, "Asthma phenotypes and endotypes: an evolving paradigm for classification", Discov Med, 15, pp.243~249 (2013)
- Bartminski G, "Novel biomarkers for asthma stratification and personalized therapy", Expert Rev Mol Diagn, 15, pp.415~430 (2015)
- Anderson GP, "Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease", Lancet, 372, pp.1107~1119 (2008)
- De Gruttola VG, "Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop", Control Clin Trials, 22, pp.485~502 (2001)
- Bousquet J, "Eosinophilic inflammation in asthma", N Engl J Med, 323, pp.1033~1039 (1990)
- Marko-Varga GA, "New directions of miniaturization within the biomarker research area", Electrophoresis, 25, pp.3479~3491 (2004)
- Deckers J, "Innate immune cells in asthma", Trends Immunol, 34, pp.540~547 (2013)
- Cayrol C, "IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy", Curr Opin Immunol, 31, pp.31~37 (2014)
- Suzukawa M, "Epithelial cell-derived IL-25, but not Th17 cell-derived IL-17 or IL-17F, is crucial for murine asthma", J Immunol, 189, pp.3641~3652 (2015)
- Moro K, "Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+) Sca-1(+) lymphoid cells", Nature, 463, pp.540~544 (2010)
- Sibilano R, "Mast cell activation: a complex interplay of positive and negative signaling pathways", Eur J Immunol, 44, pp.2558~2566 (2014)
- Bochner BS, "Allergy and asthma", J Allergy Clin Immunol, 115, pp.953~959 (2005)
- Jacobsen EA, "Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation", J Immunol, 187, pp.6059~6068 (2011)
- Schuijs MJ, "Cytokine targets in airway inflammation", Curr Opin Pharmacol, 13, pp.351~361 (2013)
- Woodruff PG, "T-helper type 2-driven inflammation defines major subphenotypes of asthma", Am J Respir Crit Care Med, 180, pp.388~395 (2009)
- Nakagome K, "Neutrophilic inflammation in severe asthma", Int Arch Allergy Immunol, 158(Suppl 1), pp.96~102 (2012)
- Durrant DM, "Emerging roles of T helper subsets in the pathogenesis of asthma", Immunol Invest, 39, pp.526~549 (2010)
- Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma", N Engl J Med, 360, pp.973~984 (2009)
- Lim S, "Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma", Thorax, 55, pp.184~188 (2000)
- Crimi E, "Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma", Am J Respir Crit Care Med, 157, pp.4~9 (1998)
- Loutsios C, "Biomarkers of eosinophilic inflammation in asthma", Expert Rev Respir Med, 8, pp.143~150 (2014)
- Halonen M, "An epidemiologic study of interrelationships of total serum immunoglobulin E, allergy skin-test reactivity, and eosinophilia", J Allergy Clin Immunol, 69, pp.221~228 (1985)
- Sherrill DL, "Longitudinal evaluation of the association between pulmonary function and total serum IgE", Am J Respir Crit Care Med, 152, pp.98~102 (1995)
- Simpson A, "IgE antibody quantification and the probability of wheeze in preschool children", J Allergy Clin Immunol, 116, pp.744~749 (2005)
- Wenzel S, "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, 368, pp.2455~2466 (2013)
- Corren J, "Lebrikizumab treatment in adults with asthma", N Engl J Med, 365, pp.1088~1098 (2011)
- Szefler SJ, "Asthma outcomes: biomarkers", J Allergy Clin Immunol, 129(3 Suppl), pp.S9~S23 (2012)
- Baldacci S, "Allergy markers in respiratory epidemiology", Eur Respir J, 17, pp.773~790 (2001)
- Hastie AT, "Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects", J Allergy Clin Immunol, 132, pp.72~80 (2013)
- Druilhe A, "Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action", Apoptosis, 8, pp.481~495 (2003)
- Massanari M, "Effect of omalizumab on peripheral blood eosinophilia in allergic asthma", Respir Med, 104, pp.188~196 (2010)
- Castro M, "Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study", Am J Respir Crit Care Med, 184, pp.1125~1132 (2011)
- Leckie MJ, "Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response", Lancet, 356, pp.2144~2148 (2000)
- Valent P, "Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field", Expert Rev Hematol, 5, pp.157~176 (2012)
- Connett GJ, "Bronchoalveolar lavage", Paediatr Respir Rev, 1, pp.52~56 (2000)
- Vijverberg SJ, "Clinical utility of asthma biomarkers: from bench to bedside", Biologics, 7, pp.199~210 (2013)
- Kips JC, "Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma", Eur Respir J Suppl, 26, pp.9~12 (1998)
- Simpson JL, "Inflammatory subtypes in asthma: assessment and identification using induced sputum", Respirology, 11, pp.54~61 (2006)
- Green RH, "Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial", Lancet, 360, pp.1715~1721 (2002)
- Berry M, "Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma", Thorax, 62, pp.1043~1049 (2007)
- Fleming L, "Use of sputum eosinophil counts to guide management in children with severe asthma", Thorax, 67, pp.193~198 (2012)
- Woodruff PG, "Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma", J Allergy Clin Immunol, 108, pp.753~758 (2001)
- Lex C, "Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests", Am J Respir Crit Care Med, 174, pp.1286~1291 (2006)
- Morris SM Jr, "New insights into the regulation of inducible nitric oxide synthesis", Am J Physiol, 266(6 Pt 1), pp.E829~E839 (1994)
- Dweik RA, "An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications", Am J Respir Crit Care Med, 184, pp.602~615 (2011)
- Amelink M, "Severe adult-onset asthma: a distinct phenotype", J Allergy Clin Immunol, 132, pp.336~341 (2013)
- McNicholl DM, "The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma", Am J Respir Crit Care Med, 186, pp.1102~1108 (2012)
- Smith AD, "Use of exhaled nitric oxide measurements to guide treatment in chronic asthma", N Engl J Med, 352, pp.2163~2173 (2005)
- Petsky HL, "A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)", Thorax, 67, pp.199~208 (2012)
- Calhoun WJ, "Comparison of physician-, biomarker-, and symptom-based strate gies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial", JAMA, 308, pp.987~997 (2012)
- Deykin A, "Targeting biologic markers in asthma--is exhaled nitric oxide the bull's-eye?", N Engl J Med, 352, pp.2233~2235 (2005)
- Gillan L, "Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility", Cancer Res, 62, pp.5358~5364 (2002)
- Sidhu SS, "Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma", Proc Natl Acad Sci U S A, 107, pp.14170~14175 (2010)
- Woodruff PG, "Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids", Proc Natl Acad Sci U S A, 104, pp.15858~15863 (2007)
- Hanania NA, "Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study", Am J Respir Crit Care Med, 187, pp.804~811 (2013)
- Cai C, "Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma", Lung, 185, pp.105~112 (2007)
- Chupp GL, "A chitinase-like protein in the lung and circulation of patients with severe asthma", N Engl J Med, 357, pp.2016~2027 (2007)
- Konradsen JR, "The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma", J Allergy Clin Immunol, 132, pp.328~335 (2013)
- Specjalski K, "YKL-40 protein correlates with the phenotype of asthma", Lung, 193, pp.189~194 (2015)
- Ober C, "Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function", N Engl J Med, 358, pp.1682~1691 (2008)
- Fens N, "External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease", Clin Exp Allergy, 41, pp.1371~1378 (2011)
- Dragonieri S, "An electronic nose in the discrimination of patients with asthma and controls", J Allergy Clin Immunol, 120, pp.856~862 (2007)
- van der Schee MP, "Predicting steroid responsiveness in patients with asthma using exhaled breath profiling", Clin Exp Allergy, 43, pp.1217~1225 (2013)
- Horvath I, "Exhaled breath condensate: methodological recommendations and unresolved questions", Eur Respir J, 26, pp.523~548 (2005)
- Tufvesson E, "Methodological improvements for measuring eicosanoids and cytokines in exhaled breath condensate", Respir Med, 100, pp.34~38 (2006)
- Montuschi P, "Exhaled leukotrienes and prostaglandins in asthma", J Allergy Clin Immunol, 109, pp.615~620 (2002)
- Fireman E, "Hydrogen peroxide in exhaled breath condensate (EBC) vs eosinophil count in induced sputum (IS) in parenchymal vs airways lung diseases", Inflammation, 30, pp.44~51 (2007)
- Koh GC, "Eosinophil cationic protein: is it useful in asthma? A systematic review", Respir Med, 101, pp.696~705 (2007)
- Bartoli ML, "Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation", Respir Med, 98, pp.184~193 (2004)
- Prehn A, "Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood", Pediatr Allergy Immunol, 11, pp.87~94 (2000)
- Kumar SD, "Airway mucosal blood flow in bronchial asthma", Am J Respir Crit Care Med, 158, pp.153~156 (1998)
- García G, "Increased exhaled breath temperature in subjects with uncontrolled asthma", Int J Tuberc Lung Dis, 17, pp.969~972 (2013)
- Chan IS, "Personalized medicine: progress and promise", Annu Rev Genomics Hum Genet, 12, pp.217~244 (2011)
- Cowan DC, "Biomarker-based asthma phenotypes of corticosteroid response", J Allergy Clin Immunol, 135, pp.877~883 (2015)